Expert Views from Pharma and Biotech Industry Leaders
Refine Search
Pharmaceutical
Michael Jewell, healthcare partner at sell-side mergers and acquisitions (M&A) advisory firm Cavendish Corporate Finance, writes an Expert View piece on the potentially busy year ahead for dealmaking in the pharma sector. 1 March 2018
Biotechnology
Edward Jones, a policy and communications consultant at independent London-based strategic communications firm GK Strategy, considers the opportunities presented by the UK government's ambitious new vision in an Expert View piece. 20 February 2018
Pharmaceutical
Chris Miller, scientific lead at 3D Communications, provides his perspective on the regulatory challenges facing pharmaceutical companies that are developing opioid products designed to deter abuse in an Expert View piece. 14 February 2018
Pharmaceutical
Following last year’s Expert View on Astellas Pharma Europe’s Action on Fistula program, Christina Chale, the company’s corporate communications director, writes about her visit to Kenya to see what difference is being made to the lives of women with obstetric fistula and how the program is delivering business as well as societal benefits. 8 February 2018
Pharmaceutical
In the second of two Expert View columns to whet the appetite for the eyeforpharma Barcelona event in March, Sanofi’s Chief Data Officer (CDO), Milind Kamkolkar, expounds the possibilities of digital and the role of the CDO in this burgeoning landscape. 31 January 2018
Pharmaceutical
In a highly informative and useful Expert View piece, Heather Longden, senior marketing manager for informatics regulatory compliance at the analytical laboratory instrument and software company Waters Corporation, provides insights into the vital role data integrity plays when it comes to analytical testing for drug development. 26 January 2018
Pharmaceutical
In the first of two Expert View columns to whet the appetite for the eyeforpharma Barcelona event in March, senior executives from Boehringer Ingelheim, Teva Pharmaceutical Industries and Pfizer ask how pharma waving goodbye to brand-led strategies is changing relationships with HCPs. 24 January 2018
Generics
The cost of prescription drugs is at the forefront of discussions among patients, advocacy groups, prescribers, payers, pharmaceutical companies, and policy makers. One factor – though not the only factor – in driving the cost of prescription drugs is the availability of competing products. 19 January 2018
Pharmaceutical
Andrew Rut, chief executive of MyMeds&Me, a provider of adverse event and product quality capture software, considers in an Expert View piece how pharma’s ability to run efficient clinical trials is in danger of being compromised by GDPR and a hardening of attitudes on data privacy globally. 9 January 2018
Pharmaceutical
A decade ago, experts were predicting further integration of contract research organizations (CROs) in clinical trials. And for the most part, they were right. What used to be a vertical, top-down, fixed reporting model industry swiftly shifted to a mixed model utilizing both internal and external resources to conduct clinical trials. 21 December 2017
Pharmaceutical
In light of a recent case, David Prange and Christopher Pinahs, from USA-based law firm Robins Kaplan, provide an Expert View piece containing potentially crucial insights into improving trade secret protection. 19 December 2017
Pharmaceutical
In an Expert View piece, Rosanne Kay, partner at international law firm Reed Smith, considers when to escalate matters to an internal investigation, and how best to carry them out. 14 December 2017
Pharmaceutical
Last week, the UK government published its latest annual update on its five year strategy to combat antimicrobial resistance (AMR). AMR, widely accepted as one of the major global challenges of the 21st century, is currently implicated in around 700,000 deaths worldwide, including 50,000 in the USA and Europe alone. 7 December 2017
Pharmaceutical
The global life sciences and pharmaceuticals sector is undergoing a wave of strategic M&A activity, as incumbents make acquisitions to enhance the technological capabilities they need to keep pace with the evolution of the industry. 4 December 2017
Biotechnology
Charlie Johnson, chief executive of antibody drug conjugate (ADC) specialist ADC Bio, considers some of the challenges and solutions involved with developing ADC therapeutics in an Expert View piece. 29 November 2017
Pharmaceutical
Aside from issues concerning how to enforce second medical patents, the validity issues at the core of the Warner-Lambert case are on their way to the UK Supreme Court and have potentially significant implications for pharma patents, writes Andrew Hutchinson, a patent litigation partner at Simmons & Simmons LLP, in an Expert View piece. 23 November 2017
Pharmaceutical
In an area like oncology, innovation is needed not just with the end product, but in the way that researchers get there, finds Rik Van Mol, vice president of R&D strategy at software provider Veeva Systems, in an Expert View piece looking at a leading cancer charity’s modernization of clinical operations. 15 November 2017
Pharmaceutical
In an Expert View piece, Ulrike Gottwald-Hostalek, senior medical director at Merck KGaA, and Kerstin Brand, director of global medical affairs for diabetes at the German pharma major, consider the case of a therapy that has stood the test of time. 10 November 2017
Biotechnology
In light of the progress and potential of cell and gene therapies, Amy Grogg, senior vice president of strategy and communication at US drug wholesale company AmerisourceBergen, considers the strategies needed to overcome challenges around market access and the complexity of commercialization in an expert view column. 7 November 2017
Pharmaceutical
An expert view piece by Steven Shill, Patrick Pilch and David Friend from the BDO Center for Healthcare Excellence & Innovation, on what drug manufacturers should watch in the wake of natural disasters. 31 October 2017
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
An Expert View from Leslie Orne, president and chief executive, Trinity Life Sciences. 20 September 2024
Pharmaceutical
An Expert View from Vikas Krishan, chief digital business officer at Altimetrik. 4 September 2024
Pharmaceutical
An Expert View from the new chief executive of Gavi, the Vaccine Alliance, Sania Nishtar. 13 August 2024
Pharmaceutical
The biopharmaceutical supply chain plays a pivotal role in ensuring the seamless delivery of therapeutics to patients. However, pharmaceutical supply chains face several challenges, including regulatory complexities, global competition, and the need for innovation. 26 July 2024
Pharmaceutical
An Expert View from William Hind of Alpharmaxim and Lisa Campbell of SSI Strategy. 18 July 2024
Pharmaceutical
An Expert View from Brendan Frey, founder and chief innovation officer of Deep Genomics. 4 July 2024
Pharmaceutical
A recent survey from IDC highlights that 49% of the pharmaceutical industry believes they have achieved success in implementing artificial intelligence (AI) across the entire pharmacovigilance (PV) value chain. However, over the next two years, the industry expects this number to only marginally shift to just 51%. 17 June 2024
Biotechnology
An Expert View from Danie du Plessis, executive vice president, pharmaceutical operations at Kyowa Kirin International, and chair of the Medical Affairs Professional Society (MAPS) board. 29 May 2024
Pharmaceutical
The use of AI across all industries and sectors has been heralded as driving efficiency and accelerating innovation, with some experts even citing the technology as the biggest disruptor of our lifetime. 21 May 2024
Expert View
In an Expert View column, Bruce Leuchter, chief executive of Neurvati Neurosciences, a Blackstone Life Sciences portfolio company, outlines the importance of increased investment in research and development and innovative business models, to bring more therapies for neurological disorders to patients. 17 May 2024
Biotechnology
A new age of innovation in immunology could change medical practice and people’s lives, as long as all parts of the system learn, evolve and work together, writes Anant Murthy, General Manager, argenx EMEA, in an Expert View piece. 1 May 2024
Pharmaceutical
An Expert View from Adrienne Rivlin, a partner in LEK’s Healthcare practice. 19 April 2024
Pharmaceutical
A second Expert View piece from Xandra Neuberger, associate director, regulatory affairs and international service lead for clinical trial applications at PharmaLex. 4 April 2024
Biotechnology
An Expert View from Tomislav Kamenski, Senior Director, Therapy Area Market Access Leader, Hematology, Johnson & Johnson. 25 March 2024
Pharmaceutical
An Expert View from Rajan Jethwa, chief executive of Ellipses Pharma. 24 March 2024
Pharmaceutical
Xandra Neuberger, associate director, regulatory affairs and international service lead for clinical trial applications at PharmaLex, provides an Expert View. 29 February 2024
Pharmaceutical
In an Expert View piece, Mark Seymour, Director and Head of Media, Healthcare, at FleishmanHillard London, argues that in the ever-evolving world of healthcare, the rules of communications have not changed, they have just become more intricate, demanding a renewed focus on the essentials. 8 February 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze